|
1
|
Samadder P, Aithal R, Belan O and Krejci L: Cancer TARGETases: DSB repair as a pharmacological target. Pharmacol Ther. 161:111–131. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Crosby D, Bhatia S, Brindle KM, Coussens LM, Dive C, Emberton M, Esener S, Fitzgerald RC, Gambhir SS, Kuhn P, et al: Early detection of cancer. Science. 375:eaay90402022. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kuipers EJ, Grady WM, Lieberman D, Seufferlein T, Sung JJ, Boelens PG, van de Velde CJ and Watanabe T: Colorectal cancer. Nat Rev Dis Primers. 1:150652015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wahab MRA, Palaniyandi T, Ravi M, Viswanathan S, Baskar G, Surendran H, Gangadharan SGD and Rajendran BK: Biomarkers and biosensors for early cancer diagnosis, monitoring and prognosis. Pathol Res Pract. 250:1548122023. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bizard AH and Hickson ID: The many lives of type IA topoisomerases. J Biol Chem. 295:7138–7153. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang JC: Cellular roles of DNA topoisomerases: A molecular perspective. Nat Rev Mol Cell Biol. 3:430–440. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Schoeffler AJ and Berger JM: DNA topoisomerases: Harnessing and constraining energy to govern chromosome topology. Q Rev Biophys. 41:41–101. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Forterre P and Gadelle D: Phylogenomics of DNA topoisomerases: Their origin and putative roles in the emergence of modern organisms. Nucleic Acids Res. 37:679–692. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Spakman D, Bakx JAM, Biebricher AS, Peterman EJG, Wuite GJL and King GA: Unravelling the mechanisms of Type 1A topoisomerases using single-molecule approaches. Nucleic Acids Res. 49:5470–5492. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Uusküla-Reimand L and Wilson MD: Untangling the roles of TOP2A and TOP2B in transcription and cancer. Sci Adv. 8:eadd49202022. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Vos SM, Tretter EM, Schmidt BH and Berger JM: All tangled up: How cells direct, manage and exploit topoisomerase function. Nat Rev Mol Cell Biol. 12:827–841. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang JC, Caron PR and Kim RA: The role of DNA topoisomerases in recombination and genome stability: A double-edged sword? Cell. 62:403–406. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Champoux JJ: DNA topoisomerases: Structure, function, and mechanism. Annu Rev Biochem. 70:369–413. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chen SH, Chan NL and Hsieh TS: New mechanistic and functional insights into DNA topoisomerases. Annu Rev Biochem. 82:139–170. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Laponogov I, Veselkov DA, Crevel IMT, Pan XS, Fisher LM and Sanderson MR: Structure of an ‘open’ clamp type II topoisomerase-DNA complex provides a mechanism for DNA capture and transport. Nucleic Acids Res. 41:9911–9923. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Roca J and Wang JC: The capture of a DNA double helix by an ATP-dependent protein clamp: A key step in DNA transport by type II DNA topoisomerases. Cell. 71:833–840. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Massé E and Drolet M: Escherichia coli DNA topoisomerase I inhibits R-loop formation by relaxing transcription-induced negative supercoiling. J Biol Chem. 274:16659–16664. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Nitiss JL: DNA topoisomerase II and its growing repertoire of biological functions. Nat Rev Cancer. 9:327–337. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Linka RM, Porter ACG, Volkov A, Mielke C, Boege F and Christensen MO: C-terminal regions of topoisomerase IIalpha and IIbeta determine isoform-specific functioning of the enzymes in vivo. Nucleic Acids Res. 35:3810–3822. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jenkins JR, Ayton P, Jones T, Davies SL, Simmons DL, Harris AL, Sheer D and Hickson ID: Isolation of cDNA clones encoding the beta isozyme of human DNA topoisomerase II and localisation of the gene to chromosome 3p24. Nucleic Acids Res. 20:5587–5592. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang M, Liang C, Chen Q, Yan H, Xu J, Zhao H, Yuan X, Liu J, Lin S, Lu W and Wang F: Histone H2A phosphorylation recruits topoisomerase IIα to centromeres to safeguard genomic stability. EMBO J. 39:e1018632020. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chen T, Sun Y, Ji P, Kopetz S and Zhang W: Topoisomerase IIα in chromosome instability and personalized cancer therapy. Oncogene. 34:4019–4031. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Press MF, Sauter G, Buyse M, Bernstein L, Guzman R, Santiago A, Villalobos IE, Eiermann W, Pienkowski T, Martin M, et al: Alteration of topoisomerase II-alpha gene in human breast cancer: Association with responsiveness to anthracycline-based chemotherapy. J Clin Oncol. 29:859–867. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Heestand GM, Schwaederle M, Gatalica Z, Arguello D and Kurzrock R: Topoisomerase expression and amplification in solid tumours: Analysis of 24,262 patients. Eur J Cancer. 83:80–87. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ren L, Liu J, Gou K and Xing C: Copy number variation and high expression of DNA topoisomerase II alpha predict worse prognosis of cancer: A meta-analysis. J Cancer. 9:2082–2092. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Boot A, Liu M, Stantial N, Shah V, Yu W, Nitiss KC, Nitiss JL, Jinks-Robertson S and Rozen SG: Recurrent mutations in topoisomerase IIα cause a previously undescribed mutator phenotype in human cancers. Proc Natl Acad Sci USA. 119:e21140241192022. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gielniewski B, Poleszak K, Roura AJ, Szadkowska P, Jacek K, Krol SK, Guzik R, Wiechecka P, Maleszewska M, Kaza B, et al: Targeted sequencing of cancer-related genes reveals a recurrent TOP2A variant which affects DNA binding and coincides with global transcriptional changes in glioblastoma. Int J Cancer. 153:1003–1015. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hua W, Sa KD, Zhang X, Jia LT, Zhao J, Yang AG, Zhang R, Fan J and Bian K: MicroRNA-139 suppresses proliferation in luminal type breast cancer cells by targeting topoisomerase II alpha. Biochem Biophys Res Commun. 463:1077–1083. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Du X, Xue Z, Lv J and Wang H: Expression of the topoisomerase II alpha (TOP2A) gene in lung adenocarcinoma cells and the association with patient outcomes. Med Sci Monit. 26:e9291202020. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang T, Lu J, Wang R, Cao W and Xu J: TOP2A promotes proliferation and metastasis of hepatocellular carcinoma regulated by miR-144-3p. J Cancer. 13:589–601. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kou F, Sun H, Wu L, Li B, Zhang B, Wang X and Yang L: TOP2A promotes lung adenocarcinoma cells' malignant progression and predicts poor prognosis in lung adenocarcinoma. J Cancer. 11:2496–2508. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Bau JT and Kurz EU: Sodium salicylate is a novel catalytic inhibitor of human DNA topoisomerase II alpha. Biochem Pharmacol. 81:345–354. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Matias-Barrios VM, Radaeva M, Song Y, Alperstein Z, Lee AR, Schmitt V, Lee J, Ban F, Xie N, Qi J, et al: Discovery of new catalytic topoisomerase II inhibitors for anticancer therapeutics. Front Oncol. 10:6331422021. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G, et al: The 2021 WHO classification of tumors of the central nervous system: A summary. Neuro Oncol. 23:1231–1251. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Song J, Ma Q, Hu M, Qian D, Wang B and He N: The inhibition of miR-144-3p on cell proliferation and metastasis by targeting TOP2A in HCMV-positive glioblastoma cells. Molecules. 23:32592018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhang W, Blank A, Kremenetskaia I, Nitzsche A, Acker G, Vajkoczy P and Brandenburg S: CD13 expression affects glioma patient survival and influences key functions of human glioblastoma cell lines in vitro. BMC Cancer. 24:3692024. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yang H, Liu X, Zhu X, Zhang M, Wang Y, Ma M and Lv K: GINS1 promotes the proliferation and migration of glioma cells through USP15-mediated deubiquitination of TOP2A. iScience. 25:1049522022. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Liu Y, Ma J, Song JS, Zhou HY, Li JH, Luo C, Geng X and Zhao HX: DNA topoisomerase II alpha promotes the metastatic characteristics of glioma cells by transcriptionally activating β-catenin. Bioengineered. 13:2207–2216. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhang B, Pan X, Cobb GP and Anderson TA: microRNAs as oncogenes and tumor suppressors. Dev Biol. 302:1–12. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Fazeli S, Sakala M, Rakow-Penner R and Ojeda-Fournier H: Cancer in pregnancy: Breast cancer. Abdom Radiol (NY). 48:1645–1662. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A and Bray F: Cancer statistics for the year 2020: An overview. Int J Cancer. Apr 5–2021.(Epub ahead of print). View Article : Google Scholar
|
|
42
|
Harbeck N and Gnant M: Breast cancer. Lancet. 389:1134–1150. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Winters S, Martin C, Murphy D and Shokar NK: Breast cancer epidemiology, prevention, and screening. Prog Mol Biol Transl Sci. 151:1–32. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Siegel RL, Giaquinto AN and Jemal A: Cancer statistics, 2024. CA Cancer J Clin. 74:12–49. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Nielsen TO, Leung SCY, Rimm DL, Dodson A, Acs B, Badve S, Denkert C, Ellis MJ, Fineberg S, Flowers M, et al: Assessment of Ki67 in breast cancer: Updated recommendations from the international Ki67 in breast cancer working group. J Natl Cancer Inst. 113:808–819. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Lee Y, Ni J, Beretov J, Wasinger VC, Graham P and Li Y: Recent advances of small extracellular vesicle biomarkers in breast cancer diagnosis and prognosis. Mol Cancer. 22:332023. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Anderson DC and Kodukula K: Biomarkers in pharmacology and drug discovery. Biochem Pharmacol. 87:172–188. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Romero A, Martín M, Cheang MC, López García-Asenjo JA, Oliva B, He X, de la Hoya M, García Sáenz JÁ, Arroyo Fernández M, Díaz Rubio E, et al: Assessment of topoisomerase II α status in breast cancer by quantitative PCR, gene expression microarrays, immunohistochemistry, and fluorescence in situ hybridization. Am J Pathol. 178:1453–1460. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Hu H, Tong K, Tsang JY, Ko CW, Tam F, Loong TC and Tse GM: Subtyping of triple-negative breast cancers: Its prognostication and implications in diagnosis of breast origin. ESMO Open. 9:1029932024. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Lee SB, Pan J, Xiong D, Palen K, Johnson B, Lubet RA, Shoemaker RH, Green JE, Fernando RI, Sei S, et al: Striking efficacy of a vaccine targeting TOP2A for triple-negative breast cancer immunoprevention. NPJ Precis Oncol. 7:1082023. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Järvinen TAH and Liu ET: Topoisomerase IIalpha gene (TOP2A) amplification and deletion in cancer-more common than anticipated. Cytopathology. 14:309–313. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Wang J, Xu B, Yuan P, Zhang P, Li Q, Ma F and Fan Y: TOP2A amplification in breast cancer is a predictive marker of anthracycline-based neoadjuvant chemotherapy efficacy. Breast Cancer Res Treat. 135:531–537. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Chaudhary P, Janmeda P and Pareek A, Chuturgoon AA, Sharma R and Pareek A: Etiology of lung carcinoma and treatment through medicinal plants, marine plants and green synthesized nanoparticles: A comprehensive review. Biomed Pharmacother. 173:1162942024. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Monteiro Lde S, Bastos KX, Barbosa-Filho JM, de Athayde-Filho PF, Diniz Mde F and Sobral MV: Medicinal plants and other living organisms with antitumor potential against lung cancer. Evid Based Complement Alternat Med. 2014:6041522014. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Reya T, Morrison SJ, Clarke MF and Weissman IL: Stem cells, cancer, and cancer stem cells. Nature. 414:105–111. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, Beer DG, Powell CA, Riely GJ, Van Schil PE, et al: International association for the study of lung cancer/american thoracic society/European respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 6:244–285. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Kaiser AM, Gatto A, Hanson KJ, Zhao RL, Raj N, Ozawa MG, Seoane JA, Bieging-Rolett KT, Wang M, Li I, et al: p53 governs an AT1 differentiation programme in lung cancer suppression. Nature. 619:851–859. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Wu J, Zhang L, Li W, Wang L, Jia Q, Shi F, Li K, Liao L, Shi Y and Wu S: The role of TOP2A in immunotherapy and vasculogenic mimicry in non-small cell lung cancer and its potential mechanism. Sci Rep. 13:109062023. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Xue R, Zhang Q, Cao Q, Kong R, Xiang X, Liu H, Feng M, Wang F, Cheng J, Li Z, et al: Liver tumour immune microenvironment subtypes and neutrophil heterogeneity. Nature. 612:141–147. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Chen Y, Tang L, Huang W, Abisola FH, Zhang Y, Zhang G and Yao L: Identification of a prognostic cuproptosis-related signature in hepatocellular carcinoma. Biol Direct. 18:42023. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Wang J, Chenivesse X, Henglein B and Bréchot C: Hepatitis B virus integration in a cyclin A gene in a hepatocellular carcinoma. Nature. 343:555–557. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A and Roberts LR: A global view of hepatocellular carcinoma: Trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 16:589–604. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Global Burden of Disease Liver Cancer Collaboration, . Akinyemiju T, Abera S, Ahmed M, Alam N, Alemayohu MA, Allen C, Al-Raddadi R, Alvis-Guzman N, Amoako Y, et al: The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: Results from the global burden of disease study 2015. JAMA Oncol. 3:1683–1691. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Dong Y, Sun X, Zhang K, He X, Zhang Q, Song H, Xu M, Lu H and Ren R: Type IIA topoisomerase (TOP2A) triggers epithelial-mesenchymal transition and facilitates HCC progression by regulating Snail expression. Bioengineered. 12:12967–12979. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Panvichian R, Tantiwetrueangdet A, Angkathunyakul N and Leelaudomlipi S: TOP2A amplification and overexpression in hepatocellular carcinoma tissues. Biomed Res Int. 2015:3816022015. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Wang Z, Zhu Q, Li X, Ren X, Li J, Zhang Y, Zeng S, Xu L, Dong X and Zhai B: TOP2A inhibition reverses drug resistance of hepatocellular carcinoma to regorafenib. Am J Cancer Res. 12:4343–4360. 2022.PubMed/NCBI
|
|
68
|
Wong N, Yeo W, Wong WL, Wong NL, Chan KY, Mo FK, Koh J, Chan SL, Chan AT, Lai PB, et al: TOP2A overexpression in hepatocellular carcinoma correlates with early age onset, shorter patients survival and chemoresistance. Int J Cancer. 124:644–652. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Feng J, Wei X, Liu Y, Zhang Y, Li G, Xu Y, Zhou P, Zhang J, Han X, Zhang C, et al: Identification of topoisomerase 2A as a novel bone metastasis-related gene in liver hepatocellular carcinoma. Aging (Albany NY). 15:13010–13040. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Shi W, Zhang S, Ma D, Yan D, Zhang G, Cao Y, Wang Z, Wu J and Jiang C: Targeting SphK2 reverses Acquired resistance of regorafenib in hepatocellular carcinoma. Front Oncol. 10:6942020. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Krebs N, Klein L, Wegwitz F, Espinet E, Maurer HC, Tu M, Penz F, Küffer S, Xu X, Bohnenberger H, et al: Axon guidance receptor ROBO3 modulates subtype identity and prognosis via AXL-associated inflammatory network in pancreatic cancer. JCI Insight. 7:e1544752022. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Zhang CY, Liu S and Yang M: Clinical diagnosis and management of pancreatic cancer: Markers, molecular mechanisms, and treatment options. World J Gastroenterol. 28:6827–6845. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Kawai M, Fukuda A, Otomo R, Obata S, Minaga K, Asada M, Umemura A, Uenoyama Y, Hieda N, Morita T, et al: Early detection of pancreatic cancer by comprehensive serum miRNA sequencing with automated machine learning. Br J Cancer. 131:1158–1168. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Waleleng BJ, Adiwinata R, Wenas NT, Haroen H, Rotty L, Gosal F, Rotty L, Winarta J, Waleleng A and Simadibrata M: Screening of pancreatic cancer: Target population, optimal timing and how? Ann Med Surg (Lond). 84:1048142022.PubMed/NCBI
|
|
75
|
Mizrahi JD, Surana R, Valle JW and Shroff RT: Pancreatic cancer. Lancet. 395:2008–2020. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Pei YF, Yin XM and Liu XQ: TOP2A induces malignant character of pancreatic cancer through activating β-catenin signaling pathway. Biochim Biophys Acta Mol Basis Dis. 1864:197–207. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Liu SL, Cai C, Yang ZY, Wu ZY, Wu XS, Wang XF, Dong P and Gong W: DGCR5 is activated by PAX5 and promotes pancreatic cancer via targeting miR-3163/TOP2A and activating Wnt/β-catenin pathway. Int J Biol Sci. 17:498–513. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Tanaka T, Okada R, Hozaka Y, Wada M, Moriya S, Satake S, Idichi T, Kurahara H, Ohtsuka T and Seki N: Molecular pathogenesis of pancreatic ductal adenocarcinoma: Impact of miR-30c-5p and miR-30c-2-3p regulation on oncogenic genes. Cancers (Basel). 12:27312020. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Fang C, He W, Xu T, Dai J, Xu L and Sun F: Upregulation of lncRNA DGCR5 correlates with better prognosis and inhibits bladder cancer progression via transcriptionally facilitating P21 expression. J Cell Physiol. 234:6254–6262. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Siegel RL, Miller KD, Wagle NS and Jemal A: Cancer statistics, 2023. CA Cancer J Clin. 73:17–48. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Zhou C, Bisseling TM, van der Post RS and Boleij A: The influence of Helicobacter pylori, proton pump inhibitor, and obesity on the gastric microbiome in relation to gastric cancer development. Comput Struct Biotechnol J. 23:186–198. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Zhang XY and Zhang PY: Gastric cancer: Somatic genetics as a guide to therapy. J Med Genet. 54:305–312. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Chen YU, Yu Y, Lv M, Shi Q and Li X: E2F1-mediated up-regulation of TOP2A promotes viability, migration, and invasion, and inhibits apoptosis of gastric cancer cells. J Biosci. 47:842022. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Liu SJ, Dang HX, Lim DA, Feng FY and Maher CA: Long noncoding RNAs in cancer metastasis. Nat Rev Cancer. 21:446–460. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Cui Y, Pu R, Ye J, Huang H, Liao D, Yang Y, Chen W, Yao Y and He Y: LncRNA FAM230B promotes gastric cancer growth and metastasis by regulating the miR-27a-5p/TOP2A axis. Dig Dis Sci. 66:2637–2650. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Kneis B, Wirtz S, Weber K, Denz A, Gittler M, Geppert C, Brunner M, Krautz C, Siebenhüner AR, Schierwagen R, et al: Colon cancer microbiome landscaping: Differences in right- and left-sided colon cancer and a tumor microbiome-Ileal microbiome association. Int J Mol Sci. 24:32652023. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Li Y, Li B, Jiang R, Liao L, Zheng C, Yuan J, Zeng L, Hu K, Zhang Y, Mei W, et al: A novel screening method of DNA methylation biomarkers helps to improve the detection of colorectal cancer and precancerous lesions. Cancer Med. 12:20626–20638. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Zhu C, Zhang L, Zhao S, Dai W and Xu Y, Zhang Y, Zheng H, Sheng W and Xu Y: UPF1 promotes chemoresistance to oxaliplatin through regulation of TOP2A activity and maintenance of stemness in colorectal cancer. Cell Death Dis. 12:5192021. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Zhang R, Xu J, Zhao J and Bai JH: Proliferation and invasion of colon cancer cells are suppressed by knockdown of TOP2A. J Cell Biochem. 119:7256–7263. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Carvalho RF, do Canto LM, Cury SS, Frøstrup Hansen T, Jensen LH and Rogatto SR: Drug repositioning based on the reversal of gene expression signatures identifies TOP2A as a therapeutic target for rectal cancer. Cancers (Basel). 13:54922021. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Coss A, Tosetto M, Fox EJ, Sapetto-Rebow B, Gorman S, Kennedy BN, Lloyd AT, Hyland JM, O'Donoghue DP, Sheahan K, et al: Increased topoisomerase IIalpha expression in colorectal cancer is associated with advanced disease and chemotherapeutic resistance via inhibition of apoptosis. Cancer Lett. 276:228–238. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Zou Q, Wu Y, Zhang S, Li S, Li S, Su Y, Zhang L, Li Q, Zou H, Zhang X, et al: Escherichia coli and HPV16 coinfection may contribute to the development of cervical cancer. Virulence. 15:23199622024. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Meng Q, Zhang Y, Sun H, Yang X, Hao S, Liu B, Zhou H, Wang Y and Xu ZX: Human papillomavirus-16 E6 activates the pentose phosphate pathway to promote cervical cancer cell proliferation by inhibiting G6PD lactylation. Redox Biol. 71:1031082024. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Schreiberhuber L, Barrett JE, Wang J, Redl E, Herzog C, Vavourakis CD, Sundström K, Dillner J and Widschwendter M: Cervical cancer screening using DNA methylation triage in a real-world population. Nat Med. 30:2251–2257. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Lin Z, Li X, Shi H, Cao R, Zhu L, Dang C, Sheng Y, Fan W, Yang Z and Wu S: Decoding the tumor microenvironment and molecular mechanism: Unraveling cervical cancer subpopulations and prognostic signatures through scRNA-Seq and bulk RNA-seq analyses. Front Immunol. 15:13512872024. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Zhao Q, Li H, Zhu L, Hu S, Xi X, Liu Y, Liu J and Zhong T: Bioinformatics analysis shows that TOP2A functions as a key candidate gene in the progression of cervical cancer. Biomed Rep. 13:212020.PubMed/NCBI
|
|
97
|
Wang B, Shen Y, Zou Y, Qi Z, Huang G, Xia S, Gao R, Li F and Huang Z: TOP2A promotes cell migration, invasion and epithelial-mesenchymal transition in cervical cancer via activating the PI3K/AKT signaling. Cancer Manag Res. 12:3807–3814. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Zhang J, Yu X, Guo Y and Wang D: HPV16 E6 promoting cervical cancer progression through down-regulation of miR-320a to increase TOP2A expression. Cancer Med. 13:e68752024. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Yu B, Chen L, Zhang W, Li Y, Zhang Y, Gao Y, Teng X, Zou L, Wang Q, Jia H, et al: TOP2A and CENPF are synergistic master regulators activated in cervical cancer. BMC Med Genomics. 13:1452020. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Katsumata N, Yasuda M, Isonishi S, Takahashi F, Michimae H, Kimura E, Aoki D, Jobo T, Kodama S, Terauchi F, et al: Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): A randomised, controlled, open-label trial. Lancet Oncol. 14:1020–1026. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Geng D, Zhou Y and Wang M: Advances in the role of GPX3 in ovarian cancer (Review). Int J Oncol. 64:312024. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Chekerov R, Klaman I, Zafrakas M, Könsgen D, Mustea A, Petschke B, Lichtenegger W, Sehouli J and Dahl E: Altered expression pattern of topoisomerase IIalpha in ovarian tumor epithelial and stromal cells after platinum-based chemotherapy. Neoplasia. 8:38–45. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Chekerov R, Koensgen D, Klaman I, Rosenthal A, Oskay-Oezcelik G, Mustea A, Lightenegger W, Dahl E and Sehouli J: Tumor- and stromal cell-specific expression of topoisomerase IIα and HER-2/neu in primary and recurrent ovarian cancer: Results of a prospective study. Mol Med Rep. 2:1011–1016. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Zhang K, Zheng X, Sun Y, Feng X, Wu X, Liu W, Gao C, Yan Y, Tian W and Wang Y: TOP2A modulates signaling via the AKT/mTOR pathway to promote ovarian cancer cell proliferation. Cancer Biol Ther. 25:23251262024. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Gudbrandsdottir G, Aarstad HH, Bostad L, Hjelle KM, Aarstad HJ, Bruserud Ø, Tvedt THA and Beisland C: Serum levels of the IL-6 family of cytokines predict prognosis in renal cell carcinoma (RCC). Cancer Immunol Immunother. 70:19–30. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Piao XM, Byun YJ, Zheng CM, Song SJ, Kang HW, Kim WT and Yun SJ: A new treatment landscape for RCC: Association of the human microbiome with improved outcomes in RCC. Cancers (Basel). 15:9352023. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Huang B, Ren J, Ma Q, Yang F, Pan X, Zhang Y, Liu Y, Wang C, Zhang D, Wei L, et al: A novel peptide PDHK1-241aa encoded by circPDHK1 promotes ccRCC progression via interacting with PPP1CA to inhibit AKT dephosphorylation and activate the AKT-mTOR signaling pathway. Mol Cancer. 23:342024. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Ren J, Huang B, Li W, Wang Y, Pan X, Ma Q, Liu Y, Wang X, Liang C, Zhang Y, et al: RNA-binding protein IGF2BP2 suppresses metastasis of clear cell renal cell carcinoma by enhancing CKB mRNA stability and expression. Transl Oncol. 42:1019042024. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Zhang L, Jin GZ and Li D: Tat-hspb1 suppresses clear cell renal cell carcinoma (ccRCC) growth via lysosomal membrane permeabilization. Cancers (Basel). 14:57102022. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Zhang X, Zhang G, Xu L, Bai X, Zhang J, Chen L, Lu X, Yu S, Jin Z and Sun H: Prediction of World Health Organization/international society of urological pathology (WHO/ISUP) pathological grading of clear cell renal cell carcinoma by dual-layer spectral CT. Acad Radiol. 30:2321–2328. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Huang X, Jia Y, Shi H, Fan H, Sun L, Zhang H, Wang Y, Chen J, Han J, Wang M, et al: miR-30c-2-3p suppresses the proliferation of human renal cell carcinoma cells by targeting TOP2A. Asian Biomed (Res Rev News). 17:124–135. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Zhang C, Qu Y, Xiao H, Xiao W and Liu J, Gao Y, Li M and Liu J: LncRNA SNHG3 promotes clear cell renal cell carcinoma proliferation and migration by upregulating TOP2A. Exp Cell Res. 384:1115952019. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Parker AS, Eckel-Passow JE, Serie D, Hilton T, Parasramka M, Joseph RW, Wu KJ, Cheville JC and Leibovich BC: Higher expression of topoisomerase II alpha is an independent marker of increased risk of cancer-specific death in patients with clear cell renal cell carcinoma. Eur Urol. 66:929–935. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Wang Q, Liu J, Li R, Wang S, Xu Y, Wang Y, Zhang H, Zhou Y, Zhang X, Chen X, et al: Assessing the role of programmed cell death signatures and related gene TOP2A in progression and prognostic prediction of clear cell renal cell carcinoma. Cancer Cell Int. 24:1642024. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Ashrafizadeh M, Hushmandi K, Hashemi M, Akbari ME, Kubatka P, Raei M, Koklesova L, Shahinozzaman M, Mohammadinejad R, Najafi M, et al: Role of microRNA/epithelial-to-mesenchymal transition axis in the metastasis of bladder cancer. Biomolecules. 10:11592020. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A and Bray F: Bladder cancer incidence and mortality: A global overview and recent trends. Eur Urol. 71:96–108. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Wang X, Luo L, Xu J, Lu Q, Xia H, Huang Y, Zhang L, Xie L, Jiwa H, Liang S, et al: Echinatin inhibits tumor growth and synergizes with chemotherapeutic agents against human bladder cancer cells by activating p38 and suppressing Wnt/β-catenin pathways. Genes Dis. 11:1050–1065. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Hou J, Huang H, Xie J, Yu W, Hao H and Li H: KLHDC7B as a novel diagnostic biomarker in urine exosomal mRNA promotes bladder urothelial carcinoma cell proliferation and migration, inhibits apoptosis. Mol Carcinog. 63:286–300. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Simon R, Atefy R, Wagner U, Forster T, Fijan A, Bruderer J, Wilber K, Mihatsch MJ, Gasser T and Sauter G: HER-2 and TOP2A coamplification in urinary bladder cancer. Int J Cancer. 107:764–772. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Zhang F and Wu H: MiR-599 targeting TOP2A inhibits the malignancy of bladder cancer cells. Biochem Biophys Res Commun. 570:154–161. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Zeng S, Liu A, Dai L, Yu X, Zhang Z, Xiong Q, Yang J, Liu F, Xu J, Xue Y, et al: Prognostic value of TOP2A in bladder urothelial carcinoma and potential molecular mechanisms. BMC Cancer. 19:6042019. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Schatten H: Brief overview of prostate cancer statistics, grading, diagnosis and treatment strategies. Adv Exp Med Biol. 1095:1–14. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Ilic D, Neuberger MM, Djulbegovic M and Dahm P: Screening for prostate cancer. Cochrane Database Syst Rev. 2013:Cd0047202013.PubMed/NCBI
|
|
124
|
Temilola DO, Wium M, Paccez J, Salukazana AS, Out HH, Carbone GM, Kaestner L, Cacciatore S and Zerbini LF: Potential of miRNAs in plasma extracellular vesicle for the stratification of prostate cancer in a South African population. Cancers (Basel). 15:39682023. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Moradi A, Srinivasan S, Clements J and Batra J: Beyond the biomarker role: Prostate-specific antigen (PSA) in the prostate cancer microenvironment. Cancer Metastasis Rev. 38:333–346. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Sekhoacha M, Riet K, Motloung P, Gumenku L, Adegoke A and Mashele S: Prostate cancer review: Genetics, diagnosis, treatment options, and alternative approaches. Molecules. 27:57302022. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Murphy AJ, Hughes CA, Barrett C, Magee H, Loftus B, O'Leary JJ and Sheils O: Low-level TOP2A amplification in prostate cancer is associated with HER2 duplication, androgen resistance, and decreased survival. Cancer Res. 67:2893–2898. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
de Resende MF, Vieira S, Chinen LTD, Chiappelli F, da Fonseca FP, Guimarães GC, Soares FA, Neves I, Pagotty S, Pellionisz PA, et al: Prognostication of prostate cancer based on TOP2A protein and gene assessment: TOP2A in prostate cancer. J Transl Med. 11:362013. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Huang ZG, Sun Y, Chen G, Dang YW, Lu HP, He J, Cheng JW, He ML and Li SH: MiRNA-145-5p expression and prospective molecular mechanisms in the metastasis of prostate cancer. IET Syst Biol. 15:1–13. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Sritharan S and Sivalingam N: A comprehensive review on time-tested anticancer drug doxorubicin. Life Sci. 278:1195272021. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Fathi-Karkan S, Arshad R, Rahdar A, Ramezani A, Behzadmehr R, Ghotekar S and Pandey S: Recent advancements in the targeted delivery of etoposide nanomedicine for cancer therapy: A comprehensive review. Eur J Med Chem. 259:1156762023. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Guan J, Tan X, Jiao J, Lai S, Zhang H, Kan Q, He Z, Sun M and Sun J: Iron ion-coordinated carrier-free supramolecular co-nanoassemblies of dual DNA topoisomerase-targeting inhibitors for tumor suppression. Acta Biomater. 144:121–131. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Larsen AK, Escargueil AE and Skladanowski A: Catalytic topoisomerase II inhibitors in cancer therapy. Pharmacol Ther. 99:167–181. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Ratain MJ, Kaminer LS, Bitran JD, Larson RA, Le Beau MM, Skosey C, Purl S, Hoffman PC, Wade J, Vardiman JW, et al: Acute nonlymphocytic leukemia following etoposide and cisplatin combination chemotherapy for advanced non-small-cell carcinoma of the lung. Blood. 70:1412–1417. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Montecucco A, Zanetta F and Biamonti G: Molecular mechanisms of etoposide. EXCLI J. 14:95–108. 2015.PubMed/NCBI
|
|
136
|
Choudhari AS, Mandave PC, Deshpande M, Ranjekar P and Prakash O: Phytochemicals in cancer treatment: From preclinical studies to clinical practice. Front Pharmacol. 10:16142019. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Pedersen-Bjergaard J, Philip P, Larsen SO, Andersson M, Daugaard G, Ersbøll J, Hansen SW, Hou-Jensen K, Nielsen D, Sigsgaard TC, et al: Therapy-related myelodysplasia and acute myeloid leukemia. Cytogenetic characteristics of 115 consecutive cases and risk in seven cohorts of patients treated intensively for malignant diseases in the Copenhagen series. Leukemia. 7:1975–1986. 1993.PubMed/NCBI
|
|
138
|
Bergant Loboda K, Janežič M, Štampar M, Žegura B, Filipič M and Perdih A: Substituted 4,5′-bithiazoles as catalytic inhibitors of human DNA topoisomerase IIα. J Chem Inf Model. 60:3662–3678. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Murphy MB, Kumar P, Bradley AM, Barton CE, Deweese JE and Mercer SL: Synthesis and evaluation of etoposide and podophyllotoxin analogs against topoisomerase IIα and HCT-116 cells. Bioorg Med Chem. 28:1157732020. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Li J, Sun P, Huang T, He S, Li L and Xue G: Individualized chemotherapy guided by the expression of ERCC1, RRM1, TUBB3, TYMS and TOP2A genes versus classic chemotherapy in the treatment of breast cancer: A comparative effectiveness study. Oncol Lett. 21:212021. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Hartmann JT and Lipp HP: Camptothecin and podophyllotoxin derivatives: Inhibitors of topoisomerase I and II-mechanisms of action, pharmacokinetics and toxicity profile. Drug Saf. 29:209–230. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Xu X, Persson HL and Richardson DR: Molecular pharmacology of the interaction of anthracyclines with iron. Mol Pharmacol. 68:261–271. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Bruno PM, Lu M, Dennis KA, Inam H, Moore CJ, Sheehe J, Elledge SJ, Hemann MT and Pritchard JR: The primary mechanism of cytotoxicity of the chemotherapeutic agent CX-5461 is topoisomerase II poisoning. Proc Natl Acad Sci USA. 117:4053–4060. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Bossaert M, Pipier A, Riou JF, Noirot C, Nguyên LT, Serre RF, Bouchez O, Defrancq E, Calsou P, Britton S and Gomez D: Transcription-associated topoisomerase 2α (TOP2A) activity is a major effector of cytotoxicity induced by G-quadruplex ligands. eLife. 10:e651842021. View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Olivieri M, Cho T, Álvarez-Quilón A, Li K, Schellenberg MJ, Zimmermann M, Hustedt N, Rossi SE, Adam S, Melo H, et al: A genetic map of the response to DNA damage in human cells. Cell. 182:481–496.e21. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Li TK and Liu LF: Tumor cell death induced by topoisomerase-targeting drugs. Annu Rev Pharmacol Toxicol. 41:53–77. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Luo K, Yuan J, Chen J and Lou Z: Topoisomerase IIalpha controls the decatenation checkpoint. Nat Cell Biol. 11:204–210. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Sarogni P, Brindani N, Zamborlin A, Gonnelli A, Menicagli M, Mapanao AK, Munafò F, De Vivo M and Voliani V: Tumor growth-arrest effect of tetrahydroquinazoline-derivative human topoisomerase II-alpha inhibitor in HPV-negative head and neck squamous cell carcinoma. Sci Rep. 14:91502024. View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Morizane C, Machida N, Honma Y, Okusaka T, Boku N, Kato K, Nomura S, Hiraoka N, Sekine S, Taniguchi H, et al: Effectiveness of etoposide and cisplatin vs irinotecan and cisplatin therapy for patients with advanced neuroendocrine carcinoma of the digestive system: The TOPIC-NEC phase 3 randomized clinical trial. JAMA Oncol. 8:1447–1455. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Cheng Y, Fan Y, Zhao Y, Huang D, Li X, Zhang P, Kang M, Yang N, Zhong D, Wang Z, et al: Tislelizumab plus platinum and etoposide versus placebo plus platinum and etoposide as first-line treatment for extensive-stage SCLC (RATIONALE-312): A multicenter, double-blind, placebo-controlled, randomized, phase 3 clinical trial. J Thorac Oncol. 19:1073–1085. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Pollack SM, Redman MW, Baker KK, Wagner MJ, Schroeder BA, Loggers ET, Trieselmann K, Copeland VC, Zhang S, Black G, et al: Assessment of doxorubicin and pembrolizumab in patients with advanced anthracycline-naive sarcoma: A phase 1/2 nonrandomized clinical trial. JAMA Oncol. 6:1778–1782. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Tap WD, Wagner AJ, Schöffski P, Martin-Broto J, Krarup-Hansen A, Ganjoo KN, Yen CC, Abdul Razak AR, Spira A, Kawai A, et al: Effect of doxorubicin plus olaratumab vs doxorubicin plus placebo on survival in patients with advanced soft tissue sarcomas: The ANNOUNCE randomized clinical trial. JAMA. 323:1266–1276. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Abou-Alfa GK, Shi Q, Knox JJ, Kaubisch A, Niedzwiecki D, Posey J, Tan BR Jr, Kavan P, Goel R, Lammers PE, et al: Assessment of treatment with sorafenib plus doxorubicin vs sorafenib alone in patients with advanced hepatocellular carcinoma: Phase 3 CALGB 80802 randomized clinical trial. JAMA Oncol. 5:1582–1588. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Yuan P, Kang Y, Ma F, Fan Y, Wang J, Wang X, Yue J, Luo Y, Zhang P, Li Q and Xu B: Effect of epirubicin plus paclitaxel vs epirubicin and cyclophosphamide followed by paclitaxel on disease-free survival among patients with operable ERBB2-negative and lymph node-positive breast cancer: A randomized clinical trial. JAMA Netw Open. 6:e2301222023. View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Egelston CA, Guo W, Yost SE, Ge X, Lee JS, Frankel PH, Cui Y, Ruel C, Schmolze D, Murga M, et al: Immunogenicity and efficacy of pembrolizumab and doxorubicin in a phase I trial for patients with metastatic triple-negative breast cancer. Cancer Immunol Immunother. 72:3013–3027. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Livingston MB, Jagosky MH, Robinson MM, Ahrens WA, Benbow JH, Farhangfar CJ, Foureau DM, Maxwell DM, Baldrige EA, Begic X, et al: Phase II study of pembrolizumab in combination with doxorubicin in metastatic and unresectable soft-tissue sarcoma. Clin Cancer Res. 27:6424–6431. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Singh V, Afshan T, Tyagi P, Varadwaj PK and Sahoo AK: Recent development of multi-targeted inhibitors of human topoisomerase II enzyme as potent cancer therapeutics. Int J Biol Macromol. 226:473–484. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
158
|
Liu Y, Yu K, Zhang K, Niu M, Chen Q, Liu Y, Wang L, Zhang N, Li W, Zhong X, et al: O-GlcNAcylation promotes topoisomerase IIα catalytic activity in breast cancer chemoresistance. EMBO Rep. 24:e564582023. View Article : Google Scholar : PubMed/NCBI
|
|
159
|
Amicuzi U, Grillo M, Stizzo M, Olivetta M, Tammaro S, Napolitano L, Reccia P, De Luca L, Rubinacci A, Della Rosa G, et al: Exploring the multifactorial landscape of penile cancer: A comprehensive analysis of risk factors. Diagnostics (Basel). 14:17902024. View Article : Google Scholar : PubMed/NCBI
|
|
160
|
Heumos L, Schaar AC, Lance C, Litinetskaya A, Drost F, Zappia L, Lücken MD, Strobl DC, Henao J, Curion F, et al: Best practices for single-cell analysis across modalities. Nat Rev Genet. 24:550–572. 2023. View Article : Google Scholar : PubMed/NCBI
|
